@article{0c5da49e73bb45f2bd0979f5c8b5a72a,
title = "Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project",
abstract = "INTRODUCTION: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort.METHODS: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post-positron emission tomography diagnosis and management change between {"}AUC-consistent{"} and {"}AUC-inconsistent{"} patients.RESULTS: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post-positron emission tomography diagnosis (28%-21%) and management (32%-17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%).DISCUSSION: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.",
keywords = "Alzheimer's disease, Amyloid, Appropriate use criteria, Clinical practice, Dementia, Positron emission tomography",
author = "{de Wilde}, Arno and Rik Ossenkoppele and Wiesje Pelkmans and Femke Bouwman and Colin Groot and {van Maurik}, Ingrid and Marissa Zwan and Maqsood Yaqub and Frederik Barkhof and Lammertsma, {Adriaan A} and Biessels, {Geert Jan} and Philip Scheltens and {van Berckel}, {Bart N} and {van der Flier}, {Wiesje M}",
note = "Funding Information: The VUmc Alzheimer Center is supported by Alzheimer Nederland and Stichting VUmc fonds . This study was performed within the framework of the Dutch ABIDE project and supported by a ZonMW-Memorabel grant (ABIDE; project No 733050201), in the context of the Dutch Deltaplan Dementie, and through a grant of Piramal Imaging (PET scan costs) to the Stichting Alzheimer & Neuropsychiatrie , Amsterdam. Research of the VUmc Alzheimer Center is part of the neurodegeneration research program of Amsterdam Neuroscience. The clinical database structure was developed with funding from Stichting Dioraphte . F.B. is supported by NIHR UCLH biomedical research center . W.v.d.F. is recipient of a grant by Stichting LSH-TKI (ABIDE-communication: LSHM16025). Funding Information: Conflict of interest: A.d.W., R.O., W.P., F.B., C.G., I.v.M., M.Z., M.Y., G.J.B., and B.N.M.v.B. report no disclosures. F.B serves as a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck-Serono, Roche, Novartis, Genzume, and Sanofi-aventis and has received sponsoring from EU-H2020, NOW, SMSR, TEVA, Novartis, and Toshiba and serves on the editorial boards of Radiology, Brain, Neuroradiology, MSJ, and Neurology. A.A.L. is currently the principal investigator of a study sponsored by Avid. P.S. has acquired grant support (for the institution) from GE Healthcare, Danone Research, Piramal, and MERCK. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche, Avraham, and EIP Pharma. Research programs of W.M.v.d.F. have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Imaging, Roche BV, Janssen Stellar, and Combinostics. All funding is paid to her institution.The VUmc Alzheimer Center is supported by Alzheimer Nederland and Stichting VUmc fonds. This study was performed within the framework of the Dutch ABIDE project and supported by a ZonMW-Memorabel grant (ABIDE; project No 733050201), in the context of the Dutch Deltaplan Dementie, and through a grant of Piramal Imaging (PET scan costs) to the Stichting Alzheimer & Neuropsychiatrie, Amsterdam. Research of the VUmc Alzheimer Center is part of the neurodegeneration research program of Amsterdam Neuroscience. The clinical database structure was developed with funding from Stichting Dioraphte. F.B. is supported by NIHR UCLH biomedical research center. W.v.d.F. is recipient of a grant by Stichting LSH-TKI (ABIDE-communication: LSHM16025). Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2019",
month = nov,
doi = "10.1016/j.jalz.2019.07.003",
language = "English",
volume = "15",
pages = "1458--1467",
journal = "Alzheimer's & Dementia",
issn = "1552-5260",
publisher = "John Wiley & Sons Inc.",
number = "11",
}